does the va/dod ptsd guideline rate prazosin as insufficient evidence for or against?
“The VA and DOD guideline rates the evidence as insufficient for or against prazoson.”
a host said on Psychopharmacology and Psychiatry Updates, 2026-11-02, at 14:54. hear it in context → the speaker cited: the VA and DOD guideline.
the episode: Prazosin for PTSD Nightmares (at 14:54). we link the show's own page; we do not re-host audio.
first, the part that holds
the wording is real. the 2017 VA/DoD PTSD guideline did say there was "insufficient evidence to recommend for or against" prazosin for nightmares associated with PTSD, and the current guideline still rates the evidence behind prazosin as low quality.
what we found when we went and looked
we read the current guideline, the 2023 VA/DoD guideline for PTSD and acute stress disorder (version 4.0). it does not rate prazosin as "insufficient for or against" for any use. recommendation 18 says "we suggest against" prazosin for PTSD overall (weak against). recommendation 32 says "we suggest prazosin for the treatment of nightmares associated with PTSD" (weak for), and the guideline lists this among its highlighted changes. the wording the host used comes from the superseded 2017 guideline (recommendation 28b, nightmares only), which the 2023 guideline's own appendix reproduces and marks as amended.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| the VA/DoD PTSD guideline rates the evidence for prazosin as insufficient for or against its use | false | the current guideline (2023, version 4.0, still listed as the current version on the VA guideline page) gives prazosin two ratings, and neither one is 'neither for nor against.' recommendation 18 is weak against for PTSD overall. recommendation 32 is weak for nightmares associated with PTSD. one limit: the provider summary and full text we read are dated June 2023, with the full-text file showing a later edit; we found no newer version on the VA page. [1][2][3] |
| the 2017 VA/DoD guideline rated prazosin for PTSD nightmares as insufficient evidence for or against | confirmed | appendix E of the 2023 guideline reproduces 2017 recommendation 28b word for word: 'For nightmares associated with PTSD, there is insufficient evidence to recommend for or against the use of prazosin as mono- or augmentation therapy.' it is marked 'Reviewed, Amended' and maps to 2023 recommendation 32. we read this in the 2023 document's reproduction, not in the archived 2017 file itself. [2] |
| for PTSD overall, the guideline has been neutral on prazosin | false | neither version was neutral on prazosin for PTSD overall. 2017 recommendation 28a was 'we suggest against the use of prazosin as mono- or augmentation therapy' (weak against) for global symptoms. 2023 recommendation 18 is also weak against. [1][2] |
| the evidence for prazosin for nightmares is weak | confirmed | the 2023 guideline says its 'confidence in the quality of the evidence was low,' citing small samples, high heterogeneity and risk of bias. it also notes that the large VA Cooperative multisite trial found prazosin did not beat placebo for global symptoms or nightmares. it still made a weak-for recommendation because two systematic reviews that included that trial found a clinically significant benefit for nightmares. [2] |
both directions
for the speaker: the phrase is word for word from a real VA/DoD recommendation: 2017 recommendation 28b on prazosin for PTSD nightmares. the evidence is still thin. the 2023 work group rated its confidence in the evidence as low, its recommendation is only weak, and it notes that the largest and best-designed trial, a VA Cooperative multisite trial in veterans, found no benefit over placebo for nightmares or global PTSD symptoms. so anyone saying the evidence is uncertain is right in spirit.
against: the guideline in force when the episode aired (2023, version 4.0) moved off the neutral position. it now suggests prazosin for nightmares associated with PTSD (weak for, recommendation 32), and its highlights section lists that as a new weak-for recommendation. for PTSD overall, both the 2017 and 2023 versions suggest against prazosin (weak against), so on neither question does the current guideline say "insufficient for or against." for nightmares, the claim describes a rating that was replaced in 2023. for PTSD overall, it describes a rating the guideline never gave.
what this cannot say
we did not hear the surrounding minutes of the episode, so we cannot rule out that the host was explicitly describing the 2017 version. we read the 2017 wording as the 2023 guideline's appendix reproduces it, not in the archived 2017 file, because the old URL returned not found. a guideline rating is a judgment made with a method (GRADE). it is not a measurement of how well prazosin works for any one person. "weak for" and "weak against" both mean the panel judged the trade-offs close and expected patient preferences to vary. we checked the VA guideline page in this session and it still lists 2023 as current, but a later revision could change any of this.
the medication pages behind this check
sources, each one fetched and read
- U.S. Department of Veterans Affairs and Department of Defense, VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder, Provider Summary, version 4.0, June 2023 What we read there: Table 1, recommendation 18: 'We suggest against divalproex, guanfacine, ketamine, prazosin, risperidone, tiagabine, or vortioxetine for the treatment of PTSD.' (Weak against). recommendation 32: 'We suggest prazosin for the treatment of nightmares associated with PTSD.' (Weak for; Reviewed, Amended). highlights: 'Adding Weak for recommendations for prazosin for nightmares (Recommendation 32)'. Fetched 2026-11-03 (HTTP 200). https://www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Provider-Summary.pdf
- U.S. Department of Veterans Affairs and Department of Defense, VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder, full guideline, 2023 (pp. 80, 116) What we read there: p. 80: 'The Work Group's confidence in the quality of the evidence was low... The benefits of prazosin in improving nightmares slightly outweighed the potential harm of adverse events.' it also cites a 'VA Cooperative multisite trial with Veterans in which prazosin failed to improve global symptoms of PTSD and nightmares compared with placebo.' p. 116, appendix E, 2017 recommendation 28b: 'For nightmares associated with PTSD, there is insufficient evidence to recommend for or against the use of prazosin as mono- or augmentation therapy' (N/A; mapped to 2023 rec 32). 2017 rec 28a: 'For global symptoms of PTSD, we suggest against the use of prazosin as mono- or augmentation therapy' (Weak Against). Fetched 2026-11-03 (HTTP 200). https://www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPG-Edited-111624-V5-81825.pdf
- U.S. Department of Veterans Affairs, VA/DoD Clinical Practice Guidelines: Management of Posttraumatic Stress Disorder and Acute Stress Disorder (guideline index page) What we read there: lists the 2023 guideline as the current version, with a 2023 full guideline, provider summary, quick reference guide and pocket card. retired guidelines are on a separate archive page. Fetched 2026-11-03 (HTTP 200). https://www.healthquality.va.gov/guidelines/MH/ptsd/
- The Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals of Internal Medicine, 2024. PMID 38408360 What we read there: the peer-reviewed synopsis of the 2023 guideline: 34 recommendations across assessment and diagnosis, prevention, treatment, treatment of nightmares, and PTSD with co-occurring conditions. it confirms the 2023 version as the published update. Fetched 2026-11-03 (HTTP 200). https://pubmed.ncbi.nlm.nih.gov/38408360/
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam